178 related articles for article (PubMed ID: 17124578)
21. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
[TBL] [Abstract][Full Text] [Related]
22. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
23. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.
Almurjan A; Macfarlane H; Badhan RKS
J Pharm Pharmacol; 2020 Aug; 72(8):1049-1060. PubMed ID: 32346890
[TBL] [Abstract][Full Text] [Related]
24. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
[TBL] [Abstract][Full Text] [Related]
25. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.
Ozdemir V; Tyndale RF; Reed K; Herrmann N; Sellers EM; Kalow W; Naranjo CA
J Clin Psychopharmacol; 1999 Oct; 19(5):472-5. PubMed ID: 10505591
[No Abstract] [Full Text] [Related]
26. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
27. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
28. Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma.
Shin JG; Kim KA; Yoon YR; Cha IJ; Kim YH; Shin SG
J Chromatogr B Biomed Sci Appl; 1998 Aug; 713(2):452-6. PubMed ID: 9746264
[TBL] [Abstract][Full Text] [Related]
29. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
Sawamura K; Suzuki Y; Someya T
Eur J Clin Pharmacol; 2004 Oct; 60(8):553-7. PubMed ID: 15349705
[TBL] [Abstract][Full Text] [Related]
30. Determination of paroxetine in plasma by high-performance liquid chromatography for bioequivalence studies.
López-Calull C; Dominguez N
J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):393-8. PubMed ID: 10219683
[TBL] [Abstract][Full Text] [Related]
31. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
[TBL] [Abstract][Full Text] [Related]
32. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
33. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing.
van Zeeland YR; Schoemaker NJ; Haritova A; Smit JW; van Maarseveen EM; Lumeij JT; Fink-Gremmels J
J Vet Pharmacol Ther; 2013 Feb; 36(1):51-8. PubMed ID: 22435778
[TBL] [Abstract][Full Text] [Related]
35. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
Alfaro CL; Lam YW; Simpson J; Ereshefsky L
J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
[TBL] [Abstract][Full Text] [Related]
36. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
Mäenpää J; Volotinen-Maja M; Kautiainen H; Neuvonen M; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
38. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
39. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
40. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Kennedy SH; McCann SM; Masellis M; McIntyre RS; Raskin J; McKay G; Baker GB
J Clin Psychiatry; 2002 Mar; 63(3):181-6. PubMed ID: 11926715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
